Bicycle Therapeutics (BCYC) EBITDA (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly EBITDA came in at -$54.6 million in Q2 2026, up 37.0% YoY from -$39.8 million in Q2 2025, and up 16.68% on a QoQ basis from -$65.5 million in Q1 2026.
Bicycle Therapeutics (BCYC) EBITDA (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of EBITDA data on file, last reported at -$54.6 million in Q2 2026.
- Quarterly EBITDA rose 37.0% year-over-year to -$54.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$210.3 million (up 27.06% YoY) and the FY2025 annual result came in at -$247.1 million, down 17.72% from the prior year.
- EBITDA advanced to -$54.6 million in Q2 2026, from -$65.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$24.7 million in Q4 2025 to a low of -$86.6 million in Q2 2025.
- A 5-year average of -$49.1 million and a median of -$48.7 million in 2023 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 63.48% in 2025, down 121.35% in 2025.
- Tracing BCYC's EBITDA over 5 years: stood at -$32.2 million in 2022, then tumbled by 68.37% to -$54.2 million in 2023, then retreated by 24.76% to -$67.7 million in 2024, then surged by 63.48% to -$24.7 million in 2025, then tumbled by 120.82% to -$54.6 million in 2026.
- The last three EBITDA figures came in at -$54.6 million (Q2 2026), -$65.5 million (Q1 2026), and -$24.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -54.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.56 Mn |
| Mar 31, 2026 | -65.48 Mn |
| Dec 31, 2025 | -24.71 Mn |
| Sep 30, 2025 | -65.55 Mn |
| Jun 30, 2025 | -86.60 Mn |
| Mar 31, 2025 | -70.20 Mn |
| Dec 31, 2024 | -67.66 Mn |
| Sep 30, 2024 | -63.85 Mn |
| Jun 30, 2024 | -46.65 Mn |
| Mar 31, 2024 | -31.72 Mn |
| Dec 31, 2023 | -54.24 Mn |
| Sep 30, 2023 | -50.80 Mn |
| Jun 30, 2023 | -43.11 Mn |
| Mar 31, 2023 | -41.80 Mn |
| Dec 31, 2022 | -32.21 Mn |
| Sep 30, 2022 | -29.76 Mn |
| Jun 30, 2022 | -27.30 Mn |
| Mar 31, 2022 | -27.38 Mn |
| Dec 31, 2021 | -18.02 Mn |
| Sep 30, 2021 | -14.29 Mn |